Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP646335.RAf-D5MQfqw-6b341FLL4e1L9WY8kJuYZ9xysE_XU80zo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP646335.RAf-D5MQfqw-6b341FLL4e1L9WY8kJuYZ9xysE_XU80zo130_assertion type Assertion NP646335.RAf-D5MQfqw-6b341FLL4e1L9WY8kJuYZ9xysE_XU80zo130_head.
- NP646335.RAf-D5MQfqw-6b341FLL4e1L9WY8kJuYZ9xysE_XU80zo130_assertion description "[Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646335.RAf-D5MQfqw-6b341FLL4e1L9WY8kJuYZ9xysE_XU80zo130_provenance.
- NP646335.RAf-D5MQfqw-6b341FLL4e1L9WY8kJuYZ9xysE_XU80zo130_assertion evidence source_evidence_literature NP646335.RAf-D5MQfqw-6b341FLL4e1L9WY8kJuYZ9xysE_XU80zo130_provenance.
- NP646335.RAf-D5MQfqw-6b341FLL4e1L9WY8kJuYZ9xysE_XU80zo130_assertion SIO_000772 23441129 NP646335.RAf-D5MQfqw-6b341FLL4e1L9WY8kJuYZ9xysE_XU80zo130_provenance.
- NP646335.RAf-D5MQfqw-6b341FLL4e1L9WY8kJuYZ9xysE_XU80zo130_assertion wasDerivedFrom befree-20150227 NP646335.RAf-D5MQfqw-6b341FLL4e1L9WY8kJuYZ9xysE_XU80zo130_provenance.
- NP646335.RAf-D5MQfqw-6b341FLL4e1L9WY8kJuYZ9xysE_XU80zo130_assertion wasGeneratedBy ECO_0000203 NP646335.RAf-D5MQfqw-6b341FLL4e1L9WY8kJuYZ9xysE_XU80zo130_provenance.